ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ALX Oncology (NASDAQ:ALXO) in a research note published on Friday,Benzinga reports. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2025 earnings at ($2.21) EPS.

ALXO has been the subject of a number of other research reports. HC Wainwright lowered their price objective on ALX Oncology from $25.00 to $5.00 and set a “buy” rating for the company in a research report on Friday. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $12.00 to $2.00 in a research report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.50.

ALX Oncology Price Performance

ALX Oncology stock opened at $1.52 on Friday. The stock has a market capitalization of $79.91 million, a P/E ratio of -0.51 and a beta of 0.98. ALX Oncology has a 12-month low of $1.19 and a 12-month high of $17.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The firm’s 50-day moving average is $1.62 and its two-hundred day moving average is $2.36.

Insider Transactions at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani acquired 30,000 shares of the stock in a transaction on Monday, December 2nd. The stock was purchased at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the purchase, the director now directly owns 33,000 shares in the company, valued at $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 14,443 shares of company stock valued at $23,309 over the last 90 days. Corporate insiders own 33.40% of the company’s stock.

Hedge Funds Weigh In On ALX Oncology

Several institutional investors and hedge funds have recently made changes to their positions in ALXO. Marshall Wace LLP boosted its stake in ALX Oncology by 423.0% during the 2nd quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock valued at $3,833,000 after acquiring an additional 514,133 shares during the last quarter. Privium Fund Management B.V. grew its stake in ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company’s stock worth $926,000 after purchasing an additional 112,093 shares in the last quarter. Renaissance Technologies LLC increased its holdings in ALX Oncology by 87.2% in the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock valued at $2,642,000 after buying an additional 204,100 shares during the last quarter. XTX Topco Ltd acquired a new stake in ALX Oncology during the third quarter valued at approximately $578,000. Finally, Point72 Asset Management L.P. bought a new position in ALX Oncology during the 2nd quarter worth approximately $1,834,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.